Comorbidities in MS are associated with treatment intolerance and disability

Since the 1990s, an increasing number of disease-modifying therapies (DMTs) have been approved to treat multiple sclerosis (MS), bringing increasing choice and efficacy. With this has come greater complexity for patients in what should be a shared decision-making process, involving oral treatment or injections, with varying frequency of administration and need for laboratory monitoring. Risks are variable, and efficacy may be also. The complexity increases for women in childbearing years.
Source: Neurology - Category: Neurology Authors: Tags: EDITORIALS Source Type: research

Related Links:

Objectives Cortical demyelination is common in multiple sclerosis (MS) and can be extensive. Cortical lesions contribute to disability independently from white matter lesions and may form via a distinct mechanism. However, current magnetic resonance imaging methods at 3 T are insensitive to cortical, and especially subpial cortical, lesions. Subpial lesions are well seen on T2*-weighted imaging at 7 T, but T2*-weighted methods on 3 T scanners are limited by poor lesion-to-cortex and cerebrospinal fluid-to-lesion contrast. We aimed to develop and evaluate a cerebrospinal fluid–suppressed, T2*-weighted sequence optim...
Source: Investigative Radiology - Category: Radiology Tags: Original Articles Source Type: research
AbstractIntroductionChanges in the levels of circulating markers of inflammation, oxidative stress, and neurotrophic factors might be a good candidate for the prediction of cognitive impairment in multiple sclerosis (MS). Here, the correlation between the mentioned circulating markers with the Cambridge neuropsychological test automated battery (CANTAB) task outcomes was determined in MS patients.MethodsThe CANTAB (paired-associate learning (PAL), reaction time (RTI), rapid visual information processing (RVP), and spatial working memory tasks (SWM)) was completed by the patients. Accordingly, the serum levels of interferon...
Source: Neurological Sciences - Category: Neurology Source Type: research
ABSTRACT Objective: To investigate the frequency of Comorbid Fibromyalgia Syndrome and its effects on quality of life and activities of daily living without any known psychiatric problem (schizophrenia or bipolar disorder) or severe disability, other than depression, in patients with multiple sclerosis, which is known to be a chronic disease in young adults. Methods: The study included 103 patients diagnosed with multiple sclerosis, following McDonald criteria, who had relapsing remitting disease. The Fibromyalgia Impact Questionnaire, Beck Anxiety Inventory, Beck Depression Inventory, Pittsburgh Sleep Quality Index, Fatig...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
Publication date: Available online 5 October 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Ethel Ciampi, Reinaldo Uribe-San-Martin, Bernardita Soler, Karolyn Molnar, Diego Reyes, Karina Keller, Claudia Carcamo
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: November 2020Source: Multiple Sclerosis and Related Disorders, Volume 46Author(s): Jagannadha Avasarala
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Authors: Kamal A, Hosny M, Abd Elwahab A, Shawki Kamal Y, Shehata HS, Hassan A Abstract BACKGROUND: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). Aberrant expression of transcription factor forkhead box P3 (FoxP3) has been suggested to underlie different immunological disorders as FOXP3 expression is essential for T regulatory cells (Tregs) to maintain their suppressive and anti-inflammatory functions and exert immunologic self-tolerance. Interleukin-35 (IL-35) is an important immunosuppressive cytokine that is produced mainly by CD4+ FOXP3+ Tregs. OBJECTIVES: To a...
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
AbstractBackgroundMultiple sclerosis (MS) is a chronic, progressive, and neurodegenerative central nervous system disorder. MS usually causes disability, cognitive deficiency, fatigue, and depression symptoms.ObjectivesTo assess cognitive functions of people with MS (pwMS) and investigate the impact of depression, fatigue, and disability on cognitive functions.MethodsWe administered the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery to assess 200 pwMS. The Expanded Disability Status Scale (EDSS) was used to evaluate disability levels. Fatigue Severity Scale (FSS) and the Beck Depression In...
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research
tonio Uccelli Giuseppe Matarese Diego Centonze Francesca De Vito In multiple sclerosis (MS), activated T and B lymphocytes and microglial cells release various proinflammatory cytokines, promoting neuroinflammation and negatively affecting the course of the disease. The immune response homeostasis is crucially regulated by the activity of the enzyme adenosine deaminase (ADA), as evidenced in patients with genetic ADA deficiency and in those treated with cladribine tablets. We investigated in a group of patients with MS the associations of a single nucleotide polymorphism (SNP) of ADA gene with disease characteris...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
ConclusionsThis study suggests that in addition to EDSS and recent relapses, T25FW significantly predicts utility in RRMS and SPMS. These findings support the use of T25FW to supplement the EDSS and the occurrence of relapses to characterize the course of disease progression and to more accurately accrue quality-adjusted life-years in future economic evaluations of disease-modifying therapies for the treatment of RRMS.
Source: PharmacoEconomics - Category: Health Management Source Type: research
Abstract Multiple sclerosis is a chronic inflammatory demyelinating disorder of the central nervous system that eventually leads to progressive neurodegeneration and disability. Recent findings highlighted the emerging role of each target of the endocannabinoid system in controlling the symptoms and disease progression of multiple sclerosis. Therefore, multi-target modulators of the endocannabinoid system could provide a more effective pharmacological strategy as compared to the single target modulation. In this work, N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide (B2) w...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
More News: Brain | Disability | Laboratory Medicine | Multiple Sclerosis | Neurology | Women